CBER Advanced Technologies Team

What is CATT? CBER Advanced Technologies Team

FDA | NIH: Regulatory Do’s and Don’ts: Tips from FDA – CBER Segment

Advancing the Utilization and Supporting the Implementation of Innovative Manufacturing Approaches

Advancing the Utilization and Supporting the Implementation of Innovative Manufacturing Approaches

Study Data Standards Update for CBER: Your Guide to a Successful Submission

FDA Lecture: Advancing the Science of Patient Input in the Regulatory Settings

Featured Fireside Chat: FDA Perspective

Pharmaceutical Quality Symposium 2023: Quality, Supply Chain & Advanced Manufacturing – D1 – Part 4

Regulatory Best Practices for Global Access to Medicines Including Anti-TB Medicines Day 1-Session 2

OHDSI Work With The FDA Best Around Vaccine Surveillance (March 23 OHDSI Community Call)

FDA's Sentinel Initiative - Pharmacovigilance 2020

Pharmaceutical Quality Symposium 2023: Quality, Supply Chain & Advanced Manufacturing – D2 – Part 3

Advancing Generic Drug Development: Translating Science to Approval 2023 – Day 2 – Part 3

Overview of CDER’s Real-World Evidence Demonstration Projects

Computer Software Assurance (CSA): Understanding the FDA’s New Draft Guidance

Presenter - Joseph A Huber

eCTD Submission Tools and Software. Peivand Pirouzi, Ph.D.

2019 CCTS FDA Conference - View from Ground Zero: Lessons in Developing Biologic Therapeutics

Peter Marks: The Regulatory Landscape for Genome Editing

How Entrepreneurship Can Be a Force for Good | NYU Shanghai CBER

Human Factors Engineering in Medical Products Reviews (2of14) REdI 2018

Edited Version - Webinar about US Investigational New Drug (IND) Applications.

Wound Care Innovation: The call to clinical action

Generic Drugs Forum (GDF) 2024: Regulatory Considerations to Enhance Generic Drug Access-Day 2, Pt 3